Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 20/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.82 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224119 | 0.91 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9501730 | 0.91 | FDPS (0.84) | FDPSGGPS1 | |
| SCHEMBL9394634 | 0.90 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9394781 | 0.89 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9397371 | 0.89 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL6222753 | 0.89 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9730804 | 0.88 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9554030 | 0.85 | FDPS (0.74) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9501127 | 0.83 | FDPS (0.83) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9152494 | 0.81 | FDPS (0.67) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854724-B1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| US-6057306-A | ADMINISTERING BISPHOSPHONATES TO TREAT BONE DISEASE | NOVARTIS CORPORATION (US) | 2000-05-02 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| US-8012949-B2 | Pyridinium-1-yl, quinolinium-1-yl, and related compounds; parasitic infections, for example against trypanosomes; inhibiting the enzyme farnesyl diphosphate synthase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080255070-A1 | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-10-16 | — | — | US | disclosed |
| EP-0854724-B1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 2005-03-16 | — | — | EP | disclosed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| EP-0854724-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | Novartis AG (CH) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997012619-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 1997-04-10 | — | — | WO | disclosed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5296475-A | Methanediphosphonic acids and crown compounds for treatment of bone disorders or hypercalcemia | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | disclosed |
| EP-0320455-B1 | ARALIPHATYL AMINOALCANE DIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | disclosed |
| US-5190930-A | Calcium metabolism disorder | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-5110807-A | Calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255070-A1 | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS | GGPS1, FDPS, FNTA | FDPS 2/4885GGPS1 1/4885AGTR1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.